Radiation plus chemo and immunotherapy for advanced nasopharyngeal cancer
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests a combination of two types of radiation therapy (standard SBRT and low-dose radiation) along with chemotherapy and an immunotherapy drug (PD-1 antibody) for people whose nasopharyngeal cancer has come back or spread. The goal is to see if this combination can better control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have nasopharyngeal cancer that has come back or spread to other parts of the body.
- You have not had any prior treatment (like radiation, chemo, or immunotherapy) for this recurrence or spread.
- Your health is generally good (able to do daily activities without much help).
- You have at least one tumor that can safely be treated with a special high-precision radiation called SBRT.
- Your blood counts, liver, and kidney function are within acceptable ranges (your doctor will check this).
- You are not pregnant, not breastfeeding, and willing to use effective birth control during and for 3 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether adding an anti–PD-1 immunotherapy to standard chemoradiotherapy can control nasopharyngeal cancer that has come back in the local area. It may help patients live longer or have the cancer respond better compared with chemoradiotherapy alone.
This trial tests a new way to give radiation therapy after immunotherapy and chemotherapy for people with advanced nasopharyngeal cancer (NPC) that has partially shrunk. It aims to see if a different radiation schedule works better and has fewer side effects.
This trial tests a combination treatment (chemotherapy before, then chemotherapy with radiation) for advanced nasopharyngeal cancer that hasn't spread to distant sites. The goal is to improve survival and control of the disease.
This Phase 2 trial tests adding a PD-1 “immunotherapy” medicine (a type of cancer-fighting antibody) along with stereotactic body radiotherapy (very focused radiation) to treat nasopharyngeal cancer that has spread to only a few places. It may help shrink remaining visible spots after initial local radiation and see whether this “consolidation” approach improves control of the cancer.
This Phase 2 trial studies whether adding toripalimab (an immune therapy) to radiation can control nasopharyngeal cancer that has spread only to a few places. It may help by boosting the immune system while the radiation treats the tumor sites.
This trial tests combining low-dose radiation with an immunotherapy drug (toripalimab) and chemotherapy for people whose nose and throat cancer has come back or spread. The goal is to see if this combination works better than standard treatments.
Hear when a new Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.